Effect of 5-iodo-2′-deoxyuridine on vaccinia virus (orthopoxvirus) infections in mice

Antimicrobial Agents and Chemotherapy

Volumn 46, Issue 9, 2002, Pages 2842-2847

  Neyts, Johan ^a   Verbeken, Erik ^a   De Clercq, Erik ^a  

^a REGA INSTITUTE FOR MEDICAL RESEARCH   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

IDOXURIDINE; VIRUS DNA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; DNA SYNTHESIS INHIBITION; DRUG EFFECT; DRUG EFFICACY; HISTOLOGY; LUNG; MORTALITY; MOUSE; NONHUMAN; ORTHOPOXVIRUS; PRIORITY JOURNAL; PROTECTION; SCID MOUSE; SMALLPOX; VACCINIA VIRUS; VIRUS INHIBITION; VIRUS TITRATION;

EID: 0036720998     PISSN: 00664804     EISSN: None     Source Type: Journal    
DOI: 10.1128/AAC.46.9.2842-2847.2002     Document Type: Article

References (31)

1. Treatment of infections due to Herpesvirus in humans: A critical review of the state of the art
2. Human monkeypox - Kasai Oriental, Democratic Republic of Congo, February 1996-October 1997
3. Cidofovir protects mice against lethal aerosol or intranasal cowpox virus challenge
4. Poxvirus dilemmas-monkeypox, smallpox, and biologic terrorism
5. Vaccines for biodefense: A system in distress
6. Vaccinia virus inhibitors as a paradigm for the chemotherapy of poxvirus infections
7. Efficacy of phosphonyl-methoxyalkyl derivatives of adenine in experimental herpes simplex virus and vaccinia virus infections in vivo
8. A novel selective broad-spectrum anti-DNA virus agent
9. Effect of cytosine, arabinoside, iododeoxyuridine, ethyldeoxyuridine, thiocyanatodeoxy-uridine, and ribavirin on tail lesion formation in mice infected with vaccinia virus
10. Public health. Dead virus walking
11. Smallpox vaccines. New cache eases shortage worries
12. A case of human orf in immunocompromised patient treated successfully with cidofovir cream
13. Re-emergence of monkeypox in Africa: A review of the past six years
14. Outbreak of human monkeypox, Democratic Republic of Congo, 1996 to 1997
15. Treatment of vaccinial keratitis with trifluorothymidine
16. Enhanced inhibition of orthopoxvirus replication in vitro by alkoxyalkyl esters of cidofovir and cyclic cidofovir
17. Progressive vaccinia treated with ribavirin and vaccinia immune globulin
18. A mouse model of aereosol-transmitted orthopoxviral disease: Morphology of experimental aerosol-transmitted orthopoxviral disease in cowpox virus-BALB/c mouse system
19. Resolution of recalcitrant molluscum contagiosum virus lesions in human immunodeficiency virus-infected patients treated with cidofovir
20. Vaccinia pneumonia in mice. A light and electron microscopic and viral assay study
21. Re-emergence of human monkeypox in Zaire in 1996
22. Parapoxviruses are strongly inhibited in vitro by cidofovir
23. Efficacy of (S)-1-(3-hydroxy-2-phosphonyl-methoxypropyl)-cytosine for the treatment of lethal vaccinia virus infections in severe combined immune deficiency (SCID) mice
24. Efficacy of 2-amino-7-(1,3-dihydroxy-2-propoxymethyl)-purine for the treatment of vaccinia virus (orthopoxvirus) infections in mice
25. Disseminated vaccinia in a military recruit with human immunodeficiency virus (HIV) disease
26. Treatment of cowpox virus respiratory infections in mice with ribavirin as a single agent or followed sequentially by cidofovir
27. Treatment of lethal vaccinia virus respiratory infections in mice with cidofovir
28. Intranasal treatment of cowpox virus respiratory infections in mice with cidofovir
29. Effects of cidofovir on the pathogenesis of a lethal vaccinia virus respiratory infection in mice
30. Characterization of wild-type and cidofovir-resistant strains of camelpox, cowpox, monkeypox, and vaccinia viruses
31. Topical cidofovir: A novel treatment for recalcitrant molluscum contagiosum in children infected with human immunodeficiency virus 1